Asparaginase Erwinia Chrysanthemi (Recombinant)-rywn (Rylaze) — CPB 0864 | AETNA Coverage Update

TL;DR: Aetna, a CVS Health company, modified CPB 0864 covering Rylaze (asparaginase erwinia chrysanthemi recombinant-rywn), effective December 3, 2025. Here's what billing teams need to do.

This update to the Aetna Rylaze coverage policy adds Extranodal Natural Killer/T-cell Lymphoma (ENKL) and Aggressive NK-cell Leukemia (ANKL) as covered indications alongside the existing Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LBL) criteria. The primary HCPCS code for Rylaze billing is J9021, billed alongside chemotherapy administration codes 96401, 96409, 96413, and related infusion codes. If your oncology or hematology billing team handles asparaginase claims under CPB 0864 Aetna, this expansion changes your prior authorization checklist immediately.

---

Quick-Reference Table

Field	Detail Copy
Payer	Aetna, a CVS Health company
Policy	Asparaginase Erwinia Chrysanthemi (Recombinant)-rywn (Rylaze)
Policy Code	CPB 0864
Change Type	Modified
Effective Date	December 3, 2025
Impact Level	Medium
Specialties Affected	Hematology, Oncology, Pediatric Oncology
Key Action	Update prior auth templates to include ENKL and ANKL indications with hypersensitivity documentation

---

Aetna Rylaze Coverage Criteria and Medical Necessity Requirements 2025

Aetna's coverage policy for Rylaze rests on one clinical fact: the patient must have already developed a hypersensitivity reaction to an E. coli-derived asparaginase — specifically pegaspargase (Oncaspar, billed under J9266). Rylaze is the bridge drug when the first-line agent fails due to allergy. Aetna does not cover Rylaze as a first-choice asparaginase.

For ALL and LBL, medical necessity criteria are straightforward. The member must be at least one month old, must have documented hypersensitivity to E. coli-derived asparaginase, and Rylaze must be used as part of a multi-agent chemotherapy regimen. There is no age ceiling — this applies to pediatric and adult patients alike.

For ENKL and ANKL — the newly added indications in this modification — both of the following must be met:

#	Covered Indication Copy
1	The member previously received and developed hypersensitivity to an E. coli-derived asparaginase (e.g., pegaspargase).
2	Rylaze will be used in conjunction with multi-agent chemotherapy.

The real issue here is documentation. Aetna will expect clinical records that clearly show the prior hypersensitivity event before approving J9021. That means allergy documentation, prior treatment records, and the current chemotherapy protocol in your prior authorization submission. Missing any one of these will generate a claim denial.

This coverage policy applies to commercial medical plans only. For Medicare patients, Aetna directs you to Medicare Part B criteria separately — don't apply this CPB to your Medicare book.

---

Aetna Rylaze Exclusions and Non-Covered Indications

Aetna is explicit: all indications not listed in CPB 0864 are considered experimental, investigational, or unproven. There is no middle ground here.

If a prescribing oncologist wants to use Rylaze for a diagnosis outside of ALL, LBL, ENKL, or ANKL, Aetna will deny it. Off-label use in solid tumors or other lymphoma subtypes is not covered under this policy.

Also worth flagging: both legacy asparaginase products — L-asparaginase Escherichia coli (Elspar) and Asparaginase Erwinia chrysanthemi (Erwinaze) — have been discontinued. If you still have old charge masters or encounter forms referencing those products, clean them up. Billing for a discontinued drug is a compliance risk and a claim denial waiting to happen.

---

Coverage Indications at a Glance

---

Aetna Rylaze Billing Guidelines and Action Items 2025

The effective date of December 3, 2025 means this is already live. If your team hasn't updated workflows yet, do it now.

Copy Action Items

---

CPT, HCPCS, and ICD-10 Codes for Rylaze Under CPB 0864

Covered HCPCS Code (When Selection Criteria Are Met)

Code	Type	Description Copy
J9021	HCPCS	Injection, asparaginase, recombinant, (Rylaze), 0.1 mg

Other HCPCS Codes Related to CPB 0864

These codes appear in the policy for context. J9020 and J9266 are reference codes — they are not the Rylaze billing code.

Code	Type	Description Copy
J9020	HCPCS	Injection, asparaginase, not otherwise specified, 10,000 units
J9266	HCPCS	Injection, pegaspargase, per single dose vial (Oncaspar)

Chemotherapy Administration CPT Codes

Bill one of these alongside J9021 based on the documented administration route and method.

Key ICD-10-CM Diagnosis Codes

This policy covers 376 ICD-10-CM codes in total. Below are the clinically primary codes for the covered indications. Use the most specific code available for your patient's diagnosis.

The full ICD-10 list for CPB 0864 runs 376 codes. Cross-reference your patient's diagnosis against Aetna's full published list before submitting. A mismatch between diagnosis code and covered indication is a straight path to claim denial.

---